Literature DB >> 8613376

Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria.

D E Lanar1, J A Tine, C de Taisne, M C Seguin, W I Cox, J P Winslow, L A Ware, E B Kauffman, D Gordon, W R Ballou, E Paoletti, J C Sadoff.   

Abstract

NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%). Protection did not correlate with CS repeat-specific antibody responses and was abrogated by in vivo CD8+ T-cell depletion. Protection was not enhanced by modification of the subcellular localization of CSP. These results suggest the potential of poxvirus-based vectors for the development of vaccine candidates for human malaria.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8613376      PMCID： PMC173977          DOI： 10.1128/iai.64.5.1666-1671.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  53 in total

Review 1.  Rationale for the development of an engineered sporozoite malaria vaccine.

Authors:  V Nussenzweig; R S Nussenzweig
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

2.  Cloning and expression of foreign genes in vaccinia virus, using a host range selection system.

Authors:  M E Perkus; K Limbach; E Paoletti
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

3.  Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei.

Authors:  P J Romero; J P Tam; D Schlesinger; P Clavijo; H Gibson; P J Barr; R S Nussenzweig; V Nussenzweig; F Zavala
Journal:  Eur J Immunol       Date:  1988-12       Impact factor: 5.532

4.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

5.  Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells.

Authors:  M R Hollingdale; F Zavala; R S Nussenzweig; V Nussenzweig
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

6.  Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.

Authors:  A J Morgan; M Mackett; S Finerty; J R Arrand; F T Scullion; M A Epstein
Journal:  J Med Virol       Date:  1988-06       Impact factor: 2.327

7.  Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue.

Authors:  V Deubel; R M Kinney; J J Esposito; C B Cropp; A V Vorndam; T P Monath; D W Trent
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

8.  Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

Authors:  D Panicali; S W Davis; R L Weinberg; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

9.  Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen.

Authors:  A Townsend; J Bastin; K Gould; G Brownlee; M Andrew; B Coupar; D Boyle; S Chan; G Smith
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes.

Authors:  F Zavala; A H Cochrane; E H Nardin; R S Nussenzweig; V Nussenzweig
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307
View more
  12 in total

1.  Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Authors:  O J A E Ophorst; K Radosević; M J E Havenga; M G Pau; L Holterman; B Berkhout; J Goudsmit; M Tsuji
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids.

Authors:  R Wang; D L Doolan; Y Charoenvit; R C Hedstrom; M J Gardner; P Hobart; J Tine; M Sedegah; V Fallarme; J B Sacci; M Kaur; D M Klinman; S L Hoffman; W R Weiss
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 3.  Applications of pox virus vectors to vaccination: an update.

Authors:  E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Transformed Toxoplasma gondii tachyzoites expressing the circumsporozoite protein of Plasmodium knowlesi elicit a specific immune response in rhesus monkeys.

Authors:  M Di Cristina; F Ghouze; C H Kocken; S Naitza; P Cellini; D Soldati; A W Thomas; A Crisanti
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

5.  NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  J A Tine; D E Lanar; D M Smith; B T Wellde; P Schultheiss; L A Ware; E B Kauffman; R A Wirtz; C De Taisne; G S Hui; S P Chang; P Church; M R Hollingdale; D C Kaslow; S Hoffman; K P Guito; W R Ballou; J C Sadoff; E Paoletti
Journal:  Infect Immun       Date:  1996-09       Impact factor: 3.441

6.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

Review 7.  A retrospective evaluation of the role of T cells in the development of malaria vaccine.

Authors:  Moriya Tsuji
Journal:  Exp Parasitol       Date:  2009-11-26       Impact factor: 2.011

8.  Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen.

Authors:  William O Rogers; Walter R Weiss; Anita Kumar; João C Aguiar; John A Tine; Robert Gwadz; Joseph G Harre; Kalpana Gowda; Dharmendar Rathore; Sanjai Kumar; Stephen L Hoffman
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

9.  Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.

Authors:  M Sedegah; T R Jones; M Kaur; R Hedstrom; P Hobart; J A Tine; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 10.  Development of a recombinant vaccine against Japanese encephalitis.

Authors:  Rupinderjeet Kaur; Sudhanshu Vrati
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.